Telomir Pharmaceuticals Holds 2026 Annual Meeting; Directors Elected

What Happened Telomir Pharmaceuticals, Inc. (TELO) filed an 8-K reporting results of its Annual Meeting of Stockholders held on September 11, 2026 (record date July 21, 2026). Shareholders elected four director nominees — Erez Aminov, Matthew Whalen, Edward MacPherson and Matthew Del Giudice, M.D. — and ratified Salberg & Company, P.A. as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. A quorum was present.

Key Details

• Total shares outstanding as of the July 21, 2026 record date: 68,774,954; shares represented at the meeting: 47,129,480 (≈68.53%).
• Director vote totals: Erez Aminov — 43,363,662 For / 93,927 Withheld (3,671,891 broker non-votes); Matthew Whalen — 43,365,060 For / 92,529 Withheld (3,671,891 broker non-votes); Edward MacPherson — 41,779,035 For / 1,678,554 Withheld (3,671,891 broker non-votes); Matthew Del Giudice, M.D. — 41,238,011 For / 2,219,578 Withheld (3,671,891 broker non-votes).
• Auditor ratification: Salberg & Company, P.A. approved — 46,998,583 For, 69,548 Against, 61,349 Abstained.
• Proposal to allow adjournment if needed passed — 44,841,042 For, 2,271,263 Against, 17,175 Abstained.

Why It Matters These results confirm the company’s board composition and the independent auditor for 2026, both of which affect corporate governance and financial oversight. Vote counts (including the notable withheld votes for two nominees and the broker non-votes) provide investors transparency on shareholder support levels for directors. Investors who follow governance, board changes or auditor relationships may want to review the proxy materials and future filings for more context.